Skip to content

Search

Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.

Healthcare professionals’ experiences involving Aboriginal families in the paediatric ESCALATION system

The Western Australian paediatric ESCALATION system, integrating family involvement, promotes early recognition and response to a hospitalised child's deteriorating health. This study aimed to understand healthcare professionals' experiences of Aboriginal parent/carer involvement in detecting clinical deterioration in the hospital.

Early life exposure to an episode of extreme air pollution and lung function later in childhood: the Hazelwood early life follow-up (ELF) study

Children are particularly vulnerable to air pollution, but the effects of early life exposure to acute, high-intensity pollution on later lung function remain poorly understood. We assessed the association between prenatal or infant exposure to fire-related fine particulate matter (PM2.5) from a six-week coal mine fire and subsequent lung function. 

Evaluating the Scale-Up and Sustainability of the Paediatric ESCALATION System in Country Western Australia: A Multi-Methods Study

To identify factors influencing implementation and integration of the paediatric ESCALATION system in country Western Australia.

The Hospitalization Cost of Pediatric Staphylococcus aureus Bacteremia

Staphylococcus aureus bacteremia (SAB) is the most common cause of childhood sepsis contributing to pediatric intensive care unit admission. The cost of adult SAB hospitalization is well described globally, but limited costing information is available for children. To bridge this knowledge gap, we investigated the cost of hospitalization in children with SAB in Australia.

Longitudinal Study of Language of Twins at Ages 9 and 14 Years: Twinning, Zygosity, and Heritability

This unprecedented longitudinal twin study focused on the arc of language acquisition from first words to adolescence, with data collection at 2, 4, and 6 years of age, reported in four previous studies and now new data at ages 9 and 14 years.

Modified Delphi Study to Establish Consensus on an Australasian Minimum Data Set for Pediatric Stroke Rehabilitation

This study aimed to develop a consensus-derived minimum data set for childhood stroke and establish an agreed set of tools to measure key functional outcomes identified as important by childhood stroke survivors and their families. 

Glucose Metrics During School Hours in Primary School-Aged Children With Type 1 Diabetes: A Population-Based Cohort Study

School time represents a significant component of overall glycaemia for children with type 1 diabetes (T1D), and glucose levels during instructional time may be important for optimising academic progress. There is, however, limited literature regarding glycaemia during school hours. This study aimed to evaluate glucose levels during school in primary school-aged children with T1D in Western Australia (WA) and to compare these with non-school days.

FeBRILe3: Caregiver Satisfaction With Early Discharge of Febrile Infants Under 3 Months Old

Although evidence supports clinicians to "safely do less" for febrile infants assessed as low risk of serious bacterial infection (SBI), early discharge may increase caregiver concern and reduce satisfaction with care. We captured the self-reported satisfaction and concerns for families enrolled in the study of fever, blood cultures and readiness for discharge in infants less than 3 months old (FeBRILe3), a prospective safety assessment of early discharge of low-risk febrile infants, to aid evaluation of this practice. 

Model-informed precision dosing of vancomycin in children 3 months to 18 years of age using Australia-wide data

Vancomycin is used to treat serious gram-positive infections in children; however, effective dosing information for those aged 3 months to 18 years is limited. We aimed to determine an optimized dosing strategy for this age group.